CoChat

Risk of Endocrine Adverse Events in Cancer Patients Treated with PD-1 Inhibitors: A Systematic Review and Meta-Analysis

Shang, Yan hong, Zhang, Yu, Li, Jing hua, Li, Peng, Zhang, Xi · 2017 · Immunotherapy
Cited by 39

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

AIM: We conducted this meta-analysis to investigate the overall incidence and risk of endocrine complications in cancer patients treated with PD-1 inhibitors. METHODS: Pubmed, Embase and oncology conference proceedings were searched for relevant studies. RESULTS: In comparison with chemotherapy or everolimus or cetuximab control, PD-1 inhibitors significantly increased the risk of all grade hypothyroidism (relative risk: 6.38; 95% CI: 3.78-10.77; p < 0.001) and hyperthyroidism (relative risk: 5.08; 95% CI: 2.55-10.14; p < 0.001), but not for hypophysitis. When compared with ipilimumab control, the risk of all grade hyperthyroidism and hypothyroidism with PD-1 inhibitors monotherapy seemed to be higher than ipilimumab, while the risk of hypophysitis was lower than ipilimumab. CONCLUSION: Treatment with PD-1 inhibitors is associated with an increased risk of developing hypothyroidism and hyperthyroidism, but not for hypophysitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/imt-2016-0147

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 39

Metadata

Authors
Shang, Y. H., Zhang, Y., Li, J. H., Li, P., & Zhang, X.
Venue
Immunotherapy
Published
2017-02-24
Volume
9
Issue
3
Pages
261-272
ISSN
  • 1750-743X (ISSN-L)
  • 1750-7448
OpenAlex
W2591448757
Cited by
39
References
9
FWCI
0.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of Endocrine Adverse Events in Cancer Patients Treated with PD-1 Inhibitors: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.2217/imt-2016-0147
The paper
Shang, Y. H., Zhang, Y., Li, J. H., Li, P., & Zhang, X. (2017). Risk of Endocrine Adverse Events in Cancer Patients Treated with PD-1 Inhibitors: A Systematic Review and Meta-Analysis. Immunotherapy. https://doi.org/10.2217/imt-2016-0147

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.